尊龙凯时·「中国区」官方网站

2024-03-28 Grand Pharma Introduces a Global Innovative Product for the Treatment of Demodex Blepharitis and Meibomian Gland Disease with Demodex Mites

2024-03-25 The Global Innovative RDC Drug of Grand Pharma ITM-11 Is Approved to Conduct Phase III Clinical Study in China

2024-03-22 Grand Pharma Announced Annual Results for the Year Ended 31 December 2023

2024-03-11 Grand Pharma’s Two Global Innovative Ophthalmic Products Have Achieved Significant Progress. The NDA of GPN00833 Has Been Approved by the FDA, GPN00884 Has Been Approved to Conduct Phase I Clinical Study in China

2024-01-26 Grand Pharma’s Milestone in the Layout of Structural Heart Field, the Establishment of Shanghai R&D Center

2024-01-26 The IND Application in China of Grand Pharma’s Global Innovative Therapeutic Tumor Vaccine ARC01 Was Approved

2024-01-24 Grand Pharma Strategically Controls Duoputai Pharmaceutical Technology, Strengthening the Strategic Plan in Field of Cerebro-cardiovascular Disease Treatment

2024-01-24 Prof. Jingquan Zhong’s Team at Qilu Hospital Successfully Performs HeartLight X3 Balloon Laser Ablation Surgery

2024-01-24 The IND of GPN00884, a global innovative ophthalmic preparation of Grand Pharma approved by the National Medical Products Administration of China

2024-01-24 Grand Pharma’s Core Neurointerventional Products Presented at the Annual of Chinese Interventional Neuroradiolcy Society of CSA

2024-01-22 Grand Pharma’s Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Has Submitted BLA Application to US FDA

2024-01-19 Grand Pharma Strategically Acquires Tianjin Tanabe